Radiation Therapy After Mastectomy: Mistaken Assumptions

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

I am writing in reference to your “Oncology Rounds” section in the September 2000 issue of Oncology News International (page 18). In the first case, entitled “What further therapy for this woman postmastectomy?” I noted that in the answer given by I. Craig Henderson, MD, there was no specific mention of adjuvant radiation therapy.

I am writing in reference to your “Oncology Rounds” section in the September 2000 issue of Oncology News International (page 18). In the first case, entitled “What further therapy for this woman postmastectomy?” I noted that in the answer given by I. Craig Henderson, MD, there was no specific mention of adjuvant radiation therapy.

This patient had inflammatory breast cancer by definition with dermal lymphatic involvement and, in addition, on mastectomy had positive margins on the chest wall.

Although I would agree with Dr. Henderson that she should be treated with aggressive systemic therapy, she is also at high risk for locoregional recurrence and should be treated with post-mastectomy radiation.

I do agree with Dr. Henderson’s comments that upfront chemotherapy followed by “local treatment” (mastectomy and then adjuvant radiation therapy) would have been the optimal treatment sequence.

GABRIELA B. MASKO, MD
Radiation Oncology Associates, Inc.Providence, Rhode Island

In the September ONI “Oncology Rounds,” a reader asked about further treatment for a woman after mastectomy. Clearly, this woman has inflammatory breast cancer, and while I would agree with Dr. I. Craig Henderson’s approach with chemotherapy preoperatively, I do not understand his omission of the need for radiation therapy after her chemotherapy and surgery is complete.

This patient has a positive margin and dermal lymphatic invasion, and has a very high likelihood of local recurrence and requires trimodality therapy.

Please clarify this issue with Dr. Henderson. From a medical oncology standpoint, I am afraid readers will assume that chemotherapy is the only adjuvant treatment this patient will need. Without question, she needs radiation therapy as well.

ANITA JOY HILLIARD, MD
Radiation Oncology Associates of Lynchburg, Inc.Lynchburg, Virginia

Dr. Henderson Replies:

In my discussion of this case in “Oncology Rounds,” I referred to “local treatment,” stating that “many, if not most, oncologists would have treated this patient with chemotherapy before administering local treatment.” Dr. Hilliard assumed I meant mastectomy when referring to “local treatment.” Dr. Masko assumed I meant both mastectomy and adjuvant radiation therapy.

In actual practice, I always administer radiation therapy to a patient with inflammatory breast cancer. I do not always recommend mastectomy. This will depend on the completeness of the patient’s response to chemotherapy and radiation therapy.

I have a few patients who were treated with chemotherapy and radiation therapy only who are alive and free of disease for periods in excess of 10 years.

I. CRAIG HENDERSON, MD
Adjunct Professor of MedicineUniversity of California San Francisco, California

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content